GSK Lifts Guidance After Turnover Beats Expectations

GSK has revised its full-year guidance following strong first-quarter performance. The pharmaceutical company reported higher-than-expected turnover, driven by increased sales in its vaccines and specialty medicines segment. GSK now expects higher turnover growth, projecting it to be towards the upper end of the previously stated 5% to 7% range. The company also adjusted its core operating profit and core earnings per share growth forecasts to higher levels. GSK anticipates core operating profit growth of 9% to 11% and core earnings per share growth of 8% to 10%.